title: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by retinoic acids.
abstract: The effects of retinoic acid (RA) and its analogs, all-trans RA, 9-cis RA and 13-cis RA, were investigated in human breast cancer MCF-7 cells and immortalized breast epithelial cell line MCF-10A. RA inhibited the telomerase activity of MCF-7 cells in a wide range of concentrations. RA at 10 microM also inhibited the growth of MCF-7 cells in a time-dependent manner. However, no significant growth inhibition was found between untreated control and RA-treated MCF-10A cells. Moreover, a marked inhibition of telomerase activity by RA was detected early in MCF-7 cells (after 24 h of RA treatment), which was preceded by a reduction of hTERT mRNA expression (after 12 h of RA treatment). However, MCF-10A cells showed a reduction of telomerase activity and down-regulation of hTERT after 4 days of RA treatment. Simultaneous changes in hTERT mRNA expression and telomerase activity were found for MCF-10A cells. The expressions of hTR and hTEP1 telomerase component genes were not changed after RA treatment. These results indicate that the anti-breast cancer activity of RA could be mediated by its ability to down-regulate the expression of hTERT telomerase gene.
authors.affiliation: Department of Pharmacy, Pusan National University, Pusan 609-735, Korea.
authors.forename: S H
authors.initials: SH
authors.lastname: Choi
authors.forename: H K
authors.initials: HK
authors.lastname: Kang
authors.forename: E O
authors.initials: EO
authors.lastname: Im
authors.forename: Y J
authors.initials: YJ
authors.lastname: Kim
authors.forename: Y T
authors.initials: YT
authors.lastname: Bae
authors.forename: Y H
authors.initials: YH
authors.lastname: Choi
authors.forename: K H
authors.initials: KH
authors.lastname: Lee
authors.forename: H Y
authors.initials: HY
authors.lastname: Chung
authors.forename: H K
authors.initials: HK
authors.lastname: Chang
authors.forename: N D
authors.initials: ND
authors.lastname: Kim
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology*; D000077556:Alitretinoin; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology*; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D015474:Isotretinoin / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000077556:Alitretinoin; D014212:Tretinoin; D019098:Telomerase; D015474:Isotretinoin